Navigation Links
Prickly protein
Date:2/6/2014

A genetic mechanism that controls the production of a large spike-like protein on the surface of Staphylococcus aureus (staph) bacteria alters the ability of the bacteria to form clumps and to cause disease, according to a new University of Iowa study.

The new study is the first to link this genetic mechanism to the production of the giant surface protein and to clumping behavior in bacteria. It is also the first time that clumping behavior has been associated with endocarditis, a serious infection of heart valves that kills 20,000 Americans each year. The findings were published in the Dec. 2103 issue of the journal PLOS Pathogens.

Under normal conditions, staph bacteria interact with proteins in human blood to form aggregates, or clumps. This clumping behavior has been associated with pathogenesis -- the ability of bacteria to cause disease. However, the mechanisms that control clumping are not well understood.

In the process of investigating how staph bacteria regulate cell-to-cell interactions, researchers at the UI Carver College of Medicine discovered a mutant strain of staph that does not clump at all in the presence of blood proteins.

Further investigation revealed that the clumping defect is due to disruption of a genetic signaling mechanism used by bacteria to sense and respond to their environment. The study shows that when the mechanism is disrupted, the giant surface protein is overproduced -- giving the cells a spiny, or "porcupine-like" appearance -- and the bacteria lose their ability to form clumps.

Importantly, the researchers led by Alexander Horswill, PhD, associate professor of microbiology, found that this clumping defect also makes the bacteria less dangerous in an experimental model of the serious staph infection, endocarditis.

Specifically, the team showed that wild type bacteria cause much larger vegetations (aggregates of bacteria) on the heart valves and are more deadly than the mutant bacteria, which are unable to form clumps. The experimental model of the disease was a good parallel to the team's test tube experiments.

"The mutant bacteria that don't clump in test tube experiments, don't form vegetations on the heart valves," Horswill explains.

The team then created a version of the mutant bacteria that was also unable to make the giant surface protein. This strain regained the ability of form clumps and also partially regained its ability to cause disease, suggesting that the surface protein is at least partly responsible for both preventing clump formation and for reducing pathogenesis.

"Our study suggests that clumping could be a target for therapy," says Horswill. "If we could find drugs that block clumping, I think they would be potentially really useful for blocking staph infections."

Staph bacteria are the most significant cause of serious infectious disease in the United States, according to the Centers for Disease Control and Prevention (CDC). The bacteria are responsible for life-threatening conditions, including endocarditis, pneumonia, toxic shock, and sepsis. A better understanding of how staph bacteria causes disease may help improve treatment.

The team is now using screening methods to find small molecules that can block clumping. Such molecules will allow the researchers to investigate the clumping mechanism more thoroughly and may also point to therapies that might reduce the illness caused by staph infections.


'/>"/>

Contact: Jennifer Brown
jennifer-l-brown@uiowa.edu
319-356-7124
University of Iowa Health Care
Source:Eurekalert  

Related medicine news :

1. NIH scientists find mechanism that helps HIV evade antibodies, stabilize key proteins
2. Critical protein discovered for healthy cell growth in mammals
3. Researchers find changes to protein SirT1
4. 2 proteins compete for 1 port on a growth factor; 1 promotes metastasis, the other blocks it
5. NCCS scientists discover gene regulation is dependent on protein ANP32E
6. Better protein capture a boon for drug manufacturers
7. Homemade Protein Bar Recipe Looks to Cut Out Extra Additives from Health Foods, Believes Carol Newman of The BioGirl Health Show
8. New NuGo Stronger: First Non-GMO High Protein Bar with rBGH-Free Whey Protein for Serious Athletes
9. Tricky protein may help HIV vaccine development
10. Research shows molecular, protein targeting therapies may be best treatment for certain lung cancer
11. Rock And Rho: Proteins that help cancer cells groove
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Prickly protein
(Date:5/24/2017)... ... 2017 , ... Altec Products, Inc., a leader in enterprise document ... technology conference in San Diego, CA. , At nVerge 2017, Altec will be ... and enhance their Sage ERP solutions by providing improved visibility and control to the ...
(Date:5/24/2017)... ... , ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® ... for a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance ... , Dr. Bedich offers a variety of cosmetic dentistry services at his practice that ...
(Date:5/24/2017)... Lake Orion, Michigan (PRWEB) , ... ... ... is a disease affecting the female reproductive tract in which the endometrial ... the pelvic structures causing inflammation and pain. Patients experiencing painful intercourse, painful ...
(Date:5/24/2017)... ... May 24, 2017 , ... Adelberg-Montalvan Pediatric ... options for its patients on Long Island, New York. , Holistic dentistry ... and is one of the biggest trends in dentistry today. , Dentist ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Technique, technique, ... back injury when either lifting weights for strength training and exercise or simply lifting ... Center . , “Body position is everything,” Dr. Chang says. “Improper technique in lifting ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
(Date:5/9/2017)... May 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of ... Canadian Intellectual Property Office has granted Oramed a ... of Exenatide". The patent covers Oramed,s invention of ... GLP-1 is an incretin hormone that stimulates the ...
(Date:5/8/2017)... NEW YORK , May 8, 2017 ... in the transition from fee for service reimbursement. Black ... April 2017. 1.       The Market for ... 77% of physician practices with 3 or ... Compliance Technology Solutions by Q4. "Given the magnitude of ...
Breaking Medicine Technology: